Scientific commitment and partnerships

AN IMPORTANT COLLABORATION between industry and top universities

Steba_biotech_circle

Weizmann Institute (Israel)

The Weizmann Institute of Science (WIS) is at the forefront of research and treatment innovation. The collaboration with Steba biotech led to the formation of Steba Laboratories, a research centre that enables the production and rapid targeting of new compounds prior to an in-depth pre-clinical assessment.

weizmann_institute

The partnership between WEIZMANN and Steba Laboratories has already resulted in numerous projects and represents a new concept in which Steba biotech, in its capacity as an industrial and commercial partner, has access to university-based innovations at an early stage of the research.
This approach enables the early targeting of candidate compounds for different therapy indications.
As soon as a candidate compound seems to meet the industrial requirements, the WEIZMANN team proceeds with preliminary pre-clinical studies.

At present, two new families of compounds are being studied: one comprises bacteriochlorophyll conjugates with small molecules containing the RGD tripeptide for tumour targeting and the other comprises cationic molecules. The studies concern colorectal cancer and breast cancer, among others, and are based around the improvement of innate and adaptive immunity.

University of Oxford (United Kingdom)

The collaboration with the hospital and the University of Oxford is focused on the application of vascular targeted photodynamic therapy (VTP) to kidney cancer and other malignancies as part of the minimally-invasive approach strategy.

Oxford

Memorial Sloan Kettering Cancer Center (MSKCC, USA)

The collaboration with Memorial Sloan-Kettering, a global leader in cancer research and treatment, initially involved conducting clinical trials and has evolved into an active research and development programme focusing on the treatment of advanced prostate cancers as well as other solid tumours.

The active research and development programme widely benefits from the recent university collaboration between researchers at the Weizmann Institute and the main MSKCC research teams specialised in various cancers.